There have been attempts to demonstrate the effect of lapatinib on brain metastasis in HER2-positive breast cancer patients, however, the response rate of lapatinib alone for brain metastasis was utmost 3–6% [14–20]. The gene discussed is ERBB2; the disease is breast cancer.